Lixte Biotechnology Secures $5 Million in Private Placement to Boost Growth

Lixte Biotechnology Holdings Inc.'s Finalization of Securities in the Market

Announcement

Lixte Biotechnology Holdings, Inc., a pharmaceutical company, closed its private placement with valuable investors for the sale and purchase of $5.0 million of shares of common stock, a series B convertible preferred stock, and common warrants. The price deal was confirmed in the market, following Nasdaq rules.

Deal (Offering)

The deal includes the total sale of 6,355,214 common warrants, 2,382,084 shares of common stock, and 3,573,130 shares of series B convertible preferred stock. The pre-funded warrants are quickly applicable at $0.00001 price, and they can be applied for anytime until exercised fully. The original applicable price of a single common warrant is $1.00 per share of common stock. The common warrants are operational with a deadline of 60 months after the final resale registration statement. After this process share will be declared effective from so and so date onwards.

The proceeds of Lixte are about $5.0 million, out of which $4.0 million is paid off during the closing. The total of $1.0 million will be paid after the final shares declaration and the resale registration statement registering common stock. The auction was sealed on 2ND July 2025, the company now plans to utilize the net proceeds from this deal along with the existing finance for working capital and general corporate reasons.

To the offering and closing of the deal, Spartan Capital Securities, LLC was the exclusive placement agent known for the private placement. Whereas, TroyGould PC was a council to the company, and Kaufman & Canoles, PC acted as a guide to Spartan Capital Securities, LLC.

Additional

The above-mentioned securities were sold out in a private placement transaction without public offering and registration under the Securities Act of 1933. Considering this point, the securities are not allowed to be resold or reoffered in the US, excluding access to the legal registration statement or a written relief from the registration requirements of the applicable state securities law.

The securities were provided only to authorized investors. With the registration rights signed with the investors, Lixte gave consent to file another registration statement with the SEC, including shares issuable upon applicable pre-funded warrants, resale of the common stock, and warrants. This $5.0 million closing benefits both investors and the company by enabling progress and contributing to the healthcare market in their ways. This will uplift the healthcare stock market and support other suitable sectors.